Yearly Archives

2019

adMare BioInnovations Appoints Dr. Mounia Azzi as Vice President, Program Development and Partnerships

By News & Events

With deep experience in corporate and business development, Dr. Azzi will work closely with adMare’s Venture Partners to build their portfolios through new program creation and advance adMare’s Mission to source therapeutically and commercially promising research from leading academic and biotech partners from across Canada to create and grow companies of scale.

Read More

adMare Academy Announces New Executive Institute Cohort to Drive the Canadian Life Sciences Industry Forward

By News & Events

With applications more than doubling for year two, the program Adjudication Committee has selected 19 executives, 10 women and 9 men, who have demonstrated impressive experience, accomplishment, and impact; and who span the Canadian industry from sea to sea (and even stretch south to the Bay Area, attracting a Canadian working at one of the world’s top biotech firms).

Read More

adMare BioInnovations Appoints Dr. Youssef Bennani as Venture Partner

By CDRD, News & Events

With more than 25 years of experience in pharmaceutical R&D leadership and management, serving most recently as Site Head and VP of R&D at Vertex Pharmaceuticals Canada Inc., Dr. Bennani will be based in Montreal, and responsible for overseeing and advancing a portfolio of drug development and commercialization projects through management of a multi-disciplinary scientific and business team.

Read More

CDRD & TRIUMF Announce Collaboration to Revolutionize the Fight Against Cancer with Targeted Alpha Therapy

By CDRD, News & Events

By combining TRIUMF’s expertise in manufacturing isotopes and radiolabelling conjugates with CDRD’s ability to identify and validate potential biological targets to develop therapeutic agents such as monoclonal antibodies, new “weaponized targeted therapies” can be created for the treatment of cancers with significant unmet medical need. In doing so, the organizations are leveraging two of Canada’s complementary national strengths to create a unique global competitive advantage; while also enabling an integrated health sciences ecosystem that bridges the gap between academic research, commercialization, and patient care in targeted alpha therapeutics.

Read More